DRG 840 Overview

DRG 840 covers inpatient admissions for patients with lymphoma and non-acute leukemia accompanied by at least one Major Complication or Comorbidity. This Diagnosis-Related Group captures higher-severity medical complexity related to hematologic malignancies, including treatment complications, organ dysfunction, or severe infection. It matters for Medicare payment because cases assigned to this Diagnosis-Related Group typically receive higher relative weights reflecting greater resource use and cost intensity during hospitalization. Accurate clinical documentation and coding determine eligibility for this Diagnosis-Related Group and thereby influence inpatient reimbursement.

• Trials of induction and consolidation regimens for aggressive lymphoma and non-acute leukemias: randomized or single-arm trials that evaluate different chemotherapy intensity levels, sequencing with immunotherapy or targeted agents, and the role of supportive-care measures during the initial inpatient-focused treatment phase. These studies enroll adult and older adult inpatients with newly diagnosed high-grade lymphoma or non-acute leukemias who require hospitalization for cytoreductive therapy, febrile neutropenia risk management, or tumor lysis prophylaxis; they seek to define regimens that maximize remission rates while minimizing short-term life-threatening complications. Results inform inpatient resource utilization, length of stay, transfusion needs, and upfront cost-effectiveness considerations that are directly relevant to hospital billing and DRG-based reimbursement.
• Comparative effectiveness and safety studies of inpatient management strategies for treatment-related complications: observational cohorts or pragmatic trials comparing protocols for management of neutropenic fever, tumor lysis syndrome, or severe cytopenias (for example different antimicrobial stewardship pathways, growth factor timing, or transfusion thresholds). These studies focus on hospitalized patients with lymphoma or non-acute leukemia who develop acute toxicities during therapy and aim to reduce morbidity, ICU transfers, and readmissions. Evidence from these studies guides clinical pathways, reduces variability in inpatient care, and helps payers and providers predict costs and set quality benchmarks tied to this DRG.
• Post-discharge outcomes and care-transition research including readmission-reduction and survivorship studies: prospective observational studies and care-model interventions that track patients after inpatient stays for lymphoma or non-acute leukemia to evaluate 30- and 90-day readmission rates, outpatient care coordination, and long-term functional outcomes. These trials enroll patients discharged after induction or complication management to test discharge planning, early outpatient follow-up, and remote monitoring strategies aimed at preventing avoidable rehospitalizations. Findings are important for bundled-payment planning, risk adjustment in reimbursement models, and designing post-acute services that reduce total cost of care for this DRG.